logo
  

Vringo Withdraws Patent Infringement Claim Against ZTE

ZTE Corp. (ZTCOY.PK,ZTCOF.PK) said that Vringo Inc. has withdrawn another infringement claim against ZTE Corp. before the UK High Court of Justice Chancery Division court.

The patent in question, relating to mobile communication standards, was asserted by Vringo to be one of its strongest Standard Essential Patent or SEP claims in its patent portfolio, and a key part of the litigation battle the Non-Practicing Entity has instigated around the world against ZTE.

Vringo has now withdrawn its claim on two of the three patents it selected out of its portfolio in this case. This withdrawal features among a series of other positive developments in the UK proceedings as the court also ordered Vringo to pay substantial sums to ZTE in legal fees, and rejected their discovery request during the pre-trial phase.

"This latest development once again showcases the shortcomings of Vringo's strategy. They are seeking injunctions on a portfolio of untested patents, before giving us a chance to engage in fair and meaningful negotiations. This withdrawal of yet another claim brought by Vringo demonstrates that even they recognize the weakness of some of these patents. We therefore believe the remaining patents should be properly tested court before any injunction is granted," stated Shen Jianfeng, Chief IPR Officer of ZTE.

ZTE said it believes that there is a worrying trend of patent trolls seeking to leverage their patent portfolio against innovative companies - using the threat of injunctions to demand broad-ranging portfolio licenses for untested SEPs.

The European Commission has recognized the potential for such actions to constitute a breach of antitrust law, and on this basis ZTE has recently made a complaint to the Commission citing Vringo's behavior as illegal.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT